RT Journal Article
SR Electronic
T1 The Canadian ALS Neuroimaging Consortium (CALSNIC) - a multicentre platform for standardized imaging and clinical studies in ALS
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.10.20142679
DO 10.1101/2020.07.10.20142679
A1 Kalra, Sanjay
A1 Khan, Muhammad
A1 Barlow, Laura
A1 Beaulieu, Christian
A1 Benatar, Michael
A1 Briemberg, Hannah
A1 Chenji, Sneha
A1 Clua, Miriam Garrido
A1 Das, Sumit
A1 Dionne, Annie
A1 Dupré, Nicolas
A1 Emery, Derek
A1 Eurich, Dean
A1 Frayne, Richard
A1 Genge, Angela
A1 Gibson, Summer
A1 Graham, Simon
A1 Hanstock, Christopher
A1 Ishaque, Abdullah
A1 Joseph, Jeffrey T.
A1 Keith, Julia
A1 Korngut, Lawrence
A1 Krebs, Dennell
A1 McCreary, Cheryl R.
A1 Pattany, Pradip
A1 Seres, Peter
A1 Shoesmith, Christen
A1 Szekeres, Trevor
A1 Tam, Fred
A1 Welsh, Robert
A1 Wilman, Alan
A1 Yang, Yee Hong
A1 Yunusova, Yana
A1 Zinman, Lorne
A1 ,
YR 2020
UL http://medrxiv.org/content/early/2020/08/13/2020.07.10.20142679.abstract
AB Background Amyotrophic lateral sclerosis (ALS) is a disabling and rapidly progressive neurodegenerative disorder. Increasing age is an important risk factor for developing ALS, thus the societal impact of this devastating disease will become more profound as the population ages. A significant hurdle to finding effective treatment has been an inability to accurately quantify cerebral degeneration associated with ALS in humans. Advanced magnetic resonance imaging (MRI) techniques hold promise in providing a set of biomarkers to assist in aiding diagnosis and in efficiently evaluating new drugs to treat ALS.Methods The Canadian ALS Neuroimaging Consortium (CALSNIC) was founded to develop and evaluate advanced MRI-based biomarkers that delineate biological heterogeneity, track disease progression, and predict survival in a large and heterogeneous sample of ALS patients.Findings CALSNIC has launched two studies to date (CALSINC-1, CALSNIC-2), acquiring multimodal neuroimaging, neurological, neuropsychological data, and neuropathological data from ALS patients and healthy controls in a prospective and longitudinal fashion from multiple centres in Canada and, more recently, the United States. Clinical and MRI protocols are harmonized across research centres and different MR vendors.Interpretation CALSNIC provides a multicentre platform for studying ALS biology and developing MRI-based biomarkers.Funding Canadian Institutes of Health Research, ALS Society of Canada, Brain Canada Foundation, Shelly Mrkonjic Research FundCompeting Interest StatementThe authors have declared no competing interest.Clinical TrialNCT02405182 and NCT03362658Clinical Protocols http://calsnic.org/ Funding StatementCALSNIC is funded by the Canadian Institutes of Health Research, the ALS Society of Canada, the Brain Canada Foundation, and the Shelly Mrkjonjic Research Fund.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the health research ethics boards of each participating site, and all participants gave written informed consent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDetails of the protocols in this manuscript will be made available at http://calsnic.org/.